Clinical trial · Interventional
Second-Line Irinotecan or Gefitinib in Docetaxel Pretreated NSCLC
A Phase II Study of Second-Line Therapy With Irinotecan or Gefitinib in Docetaxel Pretreated Patients With Non-Small Cell Lung Cancer: a New Treatment Strategy According to Clinical Predictors for Response
NCT00319800CI-TRIAL-00001338unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To determine whether in docetaxel pretreated advanced NSCLC patients with favorable clinical parameter(s) gefitinib can produce different outcomes from patients without favorable clinical parameter treated with irinotecan.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Gefitinib | Drug | Gefitinib | ALIAS |
| Irinotecan | Drug | Irinotecan | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Objective response rate
- measure
- Progression-free survival
Secondary outcomes (2)
- measure
- Overall survival
- measure
- Toxicity
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * aged 75 years or less * histologically or cytologically confirmed non-small cell lung cancer * advanced, metastatic or recurrent * ECOG performance status 0 to 2 * one prior palliative chemotherapy including docetaxel * measurable or evaluable indicator lesion(s) * normal marrow, hepatic and renal function * provision of written informed consent Exclusion Criteria: * active infection and/or severe comorbidities * pregnant or breastfed women * active CNS metastasis * active bleeding in GI tract or elsewhere
References
Publications (0)
Data not yet available
No reference posted for this study.